Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14753MR)

This product GTTS-WQ14753MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14753MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10462MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ14197MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ3230MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ297MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ10147MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ5838MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ2439MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ14400MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW